Mylan to Pay $465 Million in EpiPen Settlement
October 07 2016 - 5:40PM
Dow Jones News
Mylan NV has agreed to pay $465 million to resolve questions
about Medicaid rebates for its EpiPen injector products, in a
settlement with the U.S. Department of Justice and other government
agencies.
The settlement doesn't involve any finding of wrongdoing, Mylan
said.
Mylan Chief Executive Heather Bresch said in a prepared
statement that "this agreement is another important step in Mylan's
efforts to move forward and bring resolution to all EpiPen
Auto-Injector related matters."
The company will record a pretax charge of about $465 million in
the third quarter.
The federal government has said Mylan overcharged the
federal-state Medicaid program by millions of dollars over five
years for the EpiPen.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
October 07, 2016 17:25 ET (21:25 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Mylan NV (NASDAQ:MYL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mylan NV (NASDAQ:MYL)
Historical Stock Chart
From Apr 2023 to Apr 2024
